Search Results for: CDKN2A

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
Novel GGA1 golgi associated, gamma adaptin ear containing, ARF binding protein 1
  • TBC/RABGAPs
  • Amyloid fiber formation
Novel GGA3 golgi associated, gamma adaptin ear containing, ARF binding protein 3
  • TBC/RABGAPs
  • MET receptor recycling
  • Amyloid fiber formation
Novel GLIPR2 GLI pathogenesis related 2
  • L-cysteic acid
Novel GLIS1 GLIS family zinc finger 1
Novel GLIS2 GLIS family zinc finger 2
  • Nephronophthisis-medullary cystic kidney disease, including; Nephronophthisis (NPH) ; Nephronophthisis-like nephropathy 1; Medullary cystic kidney disease 1; Medullary cystic kidney disease 2 (MSKD2)
Novel GMNN geminin DNA replication inhibitor
  • Assembly of the pre-replicative complex
  • Activation of the pre-replicative complex
  • Switching of origins to a post-replicative state
Novel GSPT1 G1 to S phase transition 1
  • Eukaryotic Translation Termination
  • Eukaryotic Translation Termination
  • Regulation of expression of SLITs and ROBOs
  • Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)
  • Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)
  • Guanosine-5'-Diphosphate
Novel H2BC26 H2B clustered histone 26
  • Recognition and association of DNA glycosylase with site containing an affected pyrimidine
  • Cleavage of the damaged pyrimidine
  • Recognition and association of DNA glycosylase with site containing an affected purine
  • Recognition and association of DNA glycosylase with site containing an affected purine
  • Cleavage of the damaged purine
  • Cleavage of the damaged purine
  • Meiotic synapsis
  • Packaging Of Telomere Ends
  • Pre-NOTCH Transcription and Translation
  • Formation of the beta-catenin:TCF transactivating complex
  • Formation of the beta-catenin:TCF transactivating complex
  • PRC2 methylates histones and DNA
  • Condensation of Prophase Chromosomes
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • HDACs deacetylate histones
  • HATs acetylate histones
  • HATs acetylate histones
  • SIRT1 negatively regulates rRNA expression
  • ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
  • NoRC negatively regulates rRNA expression
  • NoRC negatively regulates rRNA expression
  • B-WICH complex positively regulates rRNA expression
  • DNA methylation
  • Transcriptional regulation by small RNAs
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3
  • Ub-specific processing proteases
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Nonhomologous End-Joining (NHEJ)
  • Processing of DNA double-strand break ends
  • Deposition of new CENPA-containing nucleosomes at the centromere
  • Assembly of the ORC complex at the origin of replication
  • G2/M DNA damage checkpoint
  • RNA Polymerase I Promoter Opening
  • RNA Polymerase I Promoter Escape
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Estrogen-dependent gene expression
  • Meiotic recombination
  • HCMV Early Events
  • HCMV Late Events
  • Transcriptional regulation of granulopoiesis
  • Inhibition of DNA recombination at telomere
  • Defective pyroptosis
  • Negative Regulation of CDH1 Gene Transcription
  • Amyloid fiber formation
  • Chromatin modifications during the maternal to zygotic transition (MZT)
  • Replacement of protamines by nucleosomes in the male pronucleus
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Regulation of endogenous retroelements by KRAB-ZFP proteins
  • Regulation of endogenous retroelements by KRAB-ZFP proteins
  • Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex
  • Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex
  • Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)
  • Regulation of PD-L1(CD274) transcription
Novel HGF hepatocyte growth factor
  • Platelet degranulation
  • PIP3 activates AKT signaling
  • Interleukin-7 signaling
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • MET Receptor Activation
  • Negative regulation of MET activity
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates RAS signaling
  • MET activates PI3K/AKT signaling
  • MET activates PTPN11
  • MET activates PTK2 signaling
  • MET interacts with TNS proteins
  • MET activates RAP1 and RAC1
  • MET receptor recycling
  • MET activates STAT3
  • Drug-mediated inhibition of MET activation
  • Valproic acid
  • Heparin
  • O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • ABT-510
  • Foretinib
Novel HIF1A hypoxia inducible factor 1 subunit alpha
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Cellular response to hypoxia
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Ub-specific processing proteases
  • Interleukin-4 and Interleukin-13 signaling
  • PTK6 Expression
  • PTK6 promotes HIF1A stabilization
  • Neddylation
  • STAT3 nuclear events downstream of ALK signaling
  • Regulation of PD-L1(CD274) transcription
  • Carvedilol
  • Hydralazine
  • 2-Methoxyestradiol
  • ENMD-1198
  • PX-478
  • FG-2216
  • Vadadustat
Novel HLA-DOB major histocompatibility complex, class II, DO beta
  • MHC class II antigen presentation
Novel HNRNPA2B1 heterogeneous nuclear ribonucleoprotein A2/B1
  • mRNA Splicing - Major Pathway
  • Processing of Capped Intron-Containing Pre-mRNA
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
  • Copper
  • Artenimol
Novel HNRNPC heterogeneous nuclear ribonucleoprotein C
  • SUMOylation of RNA binding proteins
  • mRNA Splicing - Major Pathway
  • Processing of Capped Intron-Containing Pre-mRNA
  • RHOBTB2 GTPase cycle
  • RHOBTB1 GTPase cycle
Novel HNRNPU heterogeneous nuclear ribonucleoprotein U
  • mRNA Splicing - Major Pathway
  • Processing of Capped Intron-Containing Pre-mRNA
  • Transcriptional regulation of brown and beige adipocyte differentiation by EBF2
Novel HRAS HRas proto-oncogene, GTPase
  • SOS-mediated signalling
  • Activation of RAS in B cells
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB4 signaling
  • Signaling by SCF-KIT
  • Signalling to RAS
  • p38MAPK events
  • p38MAPK events
  • GRB2 events in EGFR signaling
  • SHC1 events in EGFR signaling
  • Downstream signal transduction
  • GRB2 events in ERBB2 signaling
  • GRB2 events in ERBB2 signaling
  • Tie2 Signaling
  • EGFR Transactivation by Gastrin
  • DAP12 signaling
  • SHC-related events triggered by IGF1R
  • FCERI mediated MAPK activation
  • NCAM signaling for neurite out-growth
  • EPHB-mediated forward signaling
  • Ras activation upon Ca2+ influx through NMDA receptor
  • VEGFR2 mediated cell proliferation
  • CD209 (DC-SIGN) signaling
  • Constitutive Signaling by EGFRvIII
  • SHC-mediated cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • Signaling by FGFR3 in disease
  • Regulation of RAS by GAPs
  • RAF activation
  • RAF/MAP kinase cascade
  • MAP2K and MAPK activation
  • Negative regulation of MAPK pathway
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF1 fusions
  • RAS signaling downstream of NF1 loss-of-function variants
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Insulin receptor signalling cascade
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAS signaling
  • Activated NTRK2 signals through RAS
  • Erythropoietin activates RAS
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK3 signals through RAS
  • FLT3 Signaling
  • Constitutive Signaling by Overexpressed ERBB2
  • Estrogen-stimulated signaling through PRKCZ
  • RAS processing
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
  • Signaling by PDGFRA extracellular domain mutants
  • Signaling by FLT3 fusion proteins
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by RAS GAP mutants
  • Signaling by RAS GTPase mutants
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5'-Triphosphate
  • Guanosine-5'-Diphosphate
  • N,N'-DIMETHYL-N-(ACETYL)-N'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
  • Ursolic acid
  • Penile cancer
  • Cervical cancer
  • Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
  • Hepatocellular carcinoma
  • Thyroid cancer
  • Squamous cell carcinoma
  • Bladder cancer
Novel HSP90AA1 heat shock protein 90 alpha family class A member 1
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • DDX58/IFIH1-mediated induction of interferon-alpha/beta
  • vRNP Assembly
  • Regulation of actin dynamics for phagocytic cup formation
  • eNOS activation
  • Regulation of PLK1 Activity at G2/M Transition
  • Scavenging by Class F Receptors
  • Scavenging by Class F Receptors
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • HSF1 activation
  • Attenuation phase
  • HSF1-dependent transactivation
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Sema3A PAK dependent Axon repulsion
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated vascular permeability
  • Uptake and function of diphtheria toxin
  • PIWI-interacting RNA (piRNA) biogenesis
  • Anchoring of the basal body to the plasma membrane
  • Constitutive Signaling by EGFRvIII
  • Regulation of necroptotic cell death
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • Downregulation of ERBB2 signaling
  • ESR-mediated signaling
  • Extra-nuclear estrogen signaling
  • RHOBTB2 GTPase cycle
  • Estrogen-dependent gene expression
  • Chaperone Mediated Autophagy
  • Constitutive Signaling by Overexpressed ERBB2
  • Aggrephagy
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Potential therapeutics for SARS
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Assembly and release of respiratory syncytial virus (RSV) virions
  • Respiratory syncytial virus genome replication
  • Rifabutin
  • Nedocromil
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • Geldanamycin
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
  • 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
  • 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
  • 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • Quercetin
  • 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • Tanespimycin
  • SNX-5422
  • N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
  • 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
  • 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
  • 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
  • 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
  • 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
  • N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
  • 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
  • CCT-018159
  • 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
  • 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
  • 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
  • (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
  • 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
  • 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
  • 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
  • 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
  • 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
  • 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
  • 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
  • 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
  • Copper
  • Polaprezinc
  • Alvespimycin
Novel HSP90AB1 heat shock protein 90 alpha family class B member 1
  • DDX58/IFIH1-mediated induction of interferon-alpha/beta
  • Regulation of actin dynamics for phagocytic cup formation
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • HSF1 activation
  • Attenuation phase
  • HSF1-dependent transactivation
  • Sema3A PAK dependent Axon repulsion
  • Uptake and function of diphtheria toxin
  • Neutrophil degranulation
  • The NLRP3 inflammasome
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • Aryl hydrocarbon receptor signalling
  • ESR-mediated signaling
  • RHOBTB2 GTPase cycle
  • Estrogen-dependent gene expression
  • Chaperone Mediated Autophagy
  • Purinergic signaling in leishmaniasis infection
  • Potential therapeutics for SARS
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Assembly and release of respiratory syncytial virus (RSV) virions
  • Respiratory syncytial virus genome replication
  • Geldanamycin
  • 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
  • Radicicol
  • Tanespimycin
  • SNX-5422
  • CCT-018159
  • 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
  • 4-{4-[4-(3-AMINOPROPOXY)PHENYL]-1H-PYRAZOL-5-YL}-6-CHLOROBENZENE-1,3-DIOL
  • (5E)-14-CHLORO-15,17-DIHYDROXY-4,7,8,9,10,11-HEXAHYDRO-2-BENZOXACYCLOPENTADECINE-1,12(3H,13H)-DIONE
  • (5Z)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE
  • (5E)-12-CHLORO-13,15-DIHYDROXY-4,7,8,9-TETRAHYDRO-2-BENZOXACYCLOTRIDECINE-1,10(3H,11H)-DIONE
  • (5Z)-13-CHLORO-14,16-DIHYDROXY-3,4,7,8,9,10-HEXAHYDRO-1H-2-BENZOXACYCLOTETRADECINE-1,11(12H)-DIONE
  • METHYL 3-CHLORO-2-{3-[(2,5-DIHYDROXY-4-METHOXYPHENYL)AMINO]-3-OXOPROPYL}-4,6-DIHYDROXYBENZOATE
  • 2-(3-AMINO-2,5,6-TRIMETHOXYPHENYL)ETHYL 5-CHLORO-2,4-DIHYDROXYBENZOATE
  • Polaprezinc
Novel HSPA4 heat shock protein family A (Hsp70) member 4
  • Regulation of HSF1-mediated heat shock response
  • Phenethyl Isothiocyanate
Novel HSPA8 heat shock protein family A (Hsp70) member 8
  • Regulation of HSF1-mediated heat shock response
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • Attenuation phase
  • HSF1-dependent transactivation
  • Lysosome Vesicle Biogenesis
  • Golgi Associated Vesicle Biogenesis
  • CHL1 interactions
  • AUF1 (hnRNP D0) binds and destabilizes mRNA
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • mRNA Splicing - Major Pathway
  • Clathrin-mediated endocytosis
  • Protein methylation
  • GABA synthesis, release, reuptake and degradation
  • Lipophagy
  • Chaperone Mediated Autophagy
  • Late endosomal microautophagy
  • Respiratory syncytial virus genome transcription
  • PKR-mediated signaling
  • Dasatinib
  • (2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
  • Copper
  • Artenimol
Novel HUWE1 HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1
  • Neutrophil degranulation
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Syndromic X-linked mental retardation, including: Turner type (MRXST); Siderius type (MRXSSD) ; Cabezas type (MRXC); Raymond type (MRXSR); Type10 (MRXS10); Type14 (MRXS14); Mental retardation with isolated growth hormone deficiency (MRGH)

Page 4 out of 18 pages